Moxifloxacin — Class III drug recall D-1094-2023
Terminated recall by Imprimis NJOF, LLC, reported 2023-08-30, distributed nationwide. Subpotent Drug; sub-potent Bromfenac levels, below the 90.0-110.0% specification range.
| Recall number | D-1094-2023 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Imprimis NJOF, LLC, Ledgewood, NJ, United States |
| Recall initiated | 2023-08-10 |
| Classified | 2023-08-21 |
| Reported by FDA | 2023-08-30 |
| Terminated | 2024-01-22 |
| Distributed | Nationwide (US) |
| Quantity | 2,683 bottles |
| Reason classes | potency |
| NDC | 71384-0311-05 |
| Lot numbers | 22DEC047, 23FEB057 |
| Expiration dates | 2023-09-16, 2023-11-24 |
Product
Moxifloxacin - Bromfenac Sterile Ophthalmic Solution 0.5% / 0.075%, 5mL bottle, Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852 (844)-446-6979, NDC: 71384-311-05.
Reason for recall
Subpotent Drug; sub-potent Bromfenac levels, below the 90.0-110.0% specification range.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1094-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.